European Journal of Rheumatology
Original Article

A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry


Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey


Department of Statistics, Dokuz Eylul University Faculty of Science, Izmir, Turkey


Division of Rheumatology, Uludag University School of Medicine, Bursa, Turkey


Division of Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey


Division of Rheumatology, Katip Celebi University School of Medicine, Izmir, Turkey


Division of Rheumatology, Fırat University School of Medicine, Elazıg, Turkey


Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey


Division of Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey


Division of Rheumatology, Department of Internal Medicine, Selçuk University School of Medicine, Konya, Turkey


Division of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey


Division of Rheumatology, Inonu University School of Medicine, Malatya, Turkey


Master of Economics, Zitelab Aps, CEO, Frederiksberg, Denmark


Division of Rheumatology, Demiroglu Bilim University School of Medicine, Istanbul, Turkey


Division of Rheumatology, Yıldırım Beyazıt University School of Medicine, Ankara, Turkey


Division of Rheumatology, Bakırkoy Dr. Sadi Konuk Training and Research Hospital School of Medicine, Istanbul, Turkey


Division of Rheumatology, Celal Bayar University School of Medicine, Manisa, Turkey


Division of Rheumatology, Sutcu Imam University School of Medicine, Kahramanmaras, Turkey

Eur J Rheumatol 2022; 9: 82-87
DOI: 10.5152/eurjrheum.2022.21060
Read: 1749 Downloads: 746 Published: 01 April 2022

Objective: TURKBIO registry, established in 2011, is the first nationwide biological database in Turkey. This study aimed to provide an overview of TURKBIO data collected by June 2018.

Methods: The registry included adult patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), nonradiographic axial spondyloarthritis (nr-AxSpA), and psoriatic arthritis (PsA). Demographic and clinical features, disease activity markers, and other follow-up parameters, current and previous treat- ments, and adverse events were registered electronically at each visit using open-source software. The registration of patient-reported outcome measures was carried out electronically by the patients using touch screens.

Results: TURKBIO registry included a total of 41,145 treatment series with biologicals. There were 2,588 patients with axSpA (2,459 AS and 129 nr-axSpA), 2,036 with RA, and 428 with PsA. The total number of patients, including those with other diagnoses, was 5,718. In the follow-up period, the number of patients and also visits steadily increased by years. The yearly mean number of visits per patient was found to be 2.3. Significant improvements in disease activity and health assessment parameters were observed following the biological treatments. Biologics were often given in combination with a con- ventional synthetic disease-modifying antirheumatic drug in patients with RA. Infections were the most commonly seen adverse events, followed by allergic reactions. Tuberculosis was observed in 12 patients, malignancy in 18, and treatment-related mortality in 31.

Conclusion: TURKBIO provided a valuable real-life experience with the use of biologics in rheumatic diseases in Turkey.

Cite this article as: O€ nen F, Can G, C􏰀 apar S, et al. A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry.Eur J Rheumatol. 2022;9(2):82-87.

EISSN 2148-4279